| Timothy J Shininger, LCSW LMFT | |
|
1317 W Grand Ave, Port Washington, WI 53074-2075 | |
| (262) 284-5789 | |
| (262) 284-5907 |
| Full Name | Timothy J Shininger |
|---|---|
| Gender | Male |
| Speciality | Marriage & Family Therapist |
| Location | 1317 W Grand Ave, Port Washington, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346294816 | NPI | - | NPPES |
| 39730900 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 4271-123 (Wisconsin) | Primary |
| 106H00000X | Marriage & Family Therapist | 406-124 (Wisconsin) | Primary |
| Entity Name | Comprehensive Counseling Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881600807 PECOS PAC ID: 9234164153 Enrollment ID: O20050929000491 |
News Archive
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) on Wednesday, Gabriel Chamie of the University of California, San Francisco "discussed outcomes in a routine linkage-to-care strategy versus and an enhanced strategy for accelerated antiretroviral therapy (ART) start in rural Uganda," the Center for Global Health Policy's "Science Speaks" blog reports.
If approved, Community Health Systems will buy Health Management Associates, resulting in a chain of 206 for-profit hospitals.
OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.
People who are obese and also have high blood pressure and other risk factors called metabolic abnormalities may experience a faster decline in their cognitive skills over time than others, according to a study published in the August 21, 2012, print issue of Neurology®, the medical journal of the American Academy of Neurology.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Timothy J Shininger, LCSW LMFT 1317 W Grand Ave, Port Washington, WI 53074-2075 Ph: (262) 284-5789 | Timothy J Shininger, LCSW LMFT 1317 W Grand Ave, Port Washington, WI 53074-2075 Ph: (262) 284-5789 |
News Archive
A majority of states are not measuring up on legislative solutions that prevent and fight cancer, according to a new report released today by the American Cancer Society Cancer Action Network (ACS CAN).
At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) on Wednesday, Gabriel Chamie of the University of California, San Francisco "discussed outcomes in a routine linkage-to-care strategy versus and an enhanced strategy for accelerated antiretroviral therapy (ART) start in rural Uganda," the Center for Global Health Policy's "Science Speaks" blog reports.
If approved, Community Health Systems will buy Health Management Associates, resulting in a chain of 206 for-profit hospitals.
OncoGenex Pharmaceuticals, Inc. announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011 (custirsen) in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.
People who are obese and also have high blood pressure and other risk factors called metabolic abnormalities may experience a faster decline in their cognitive skills over time than others, according to a study published in the August 21, 2012, print issue of Neurology®, the medical journal of the American Academy of Neurology.
› Verified 9 days ago